Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acute Octreotide or Cabergoline with Pegvisomant in Acromegaly
NCT00595140Phase 4Completed
- Sponsor
- Ludwig Maximilian University of Munich
- Start
- Jan 2008
- Primary completion
- Mar 2008
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of octreotide and cabergoline in acromegaly (3 arms), sponsored by Ludwig Maximilian University of Munich. Primary endpoint: The decrease of endogenous growth hormone at 9 hours. Started Jan 2008; status: completed.
02
Drugs
octreotidecabergoline
03
Conditions
acromegaly
Beyond the preview
Go deeper on NCT00595140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00595140.